statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant...

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has initiated the rolling submission of a New Drug...

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the...

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the...

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside...

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished...

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting...

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM Research Report) on March 25 and set a price target of $36...

Verastem's Strategic Advancements and Financial Stability Underscore Buy Rating

This price move could indicate a change in the trend, and may be a sell signal for investors...

Verastem (VSTM, $11.53) price exceeded its 50-day Moving Average on March 25, 2024

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Watchers	23,502
52-Wk Low	$4.93
52-Wk High	$15.18

Volume	13.35M
52-Wk High	$15.18
52-Wk Low	$4.93

VSTM Verastem Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community